Mesenchymal stem cells do not prevent antibody responses against human α-L-iduronidase when used to treat mucopolysaccharidosis type I.
Mucopolysaccharidosis type I (MPSI) is an autosomal recessive disease that leads to systemic lysosomal storage, which is caused by the absence of α-L-iduronidase (IDUA). Enzyme replacement therapy is recognized as the best therapeutic option for MPSI; however, high titers of anti-IDUA antibody have...
Guardado en:
Autores principales: | Priscila Keiko Matsumoto Martin, Roberta Sessa Stilhano, Vivian Yochiko Samoto, Christina Maeda Takiya, Giovani Bravin Peres, Yara Maria Correa da Silva Michelacci, Flavia Helena da Silva, Vanessa Gonçalves Pereira, Vânia D'Almeida, Fabio Luiz Navarro Marques, Andreia Hanada Otake, Roger Chammas, Sang Won Han |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1a7cce9dd89d4272a2ff63e581f5f0dc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
α-L-iduronidase therapy for mucopolysaccharidosis type I
por: Jakub Tolar, et al.
Publicado: (2008) -
Molecular Analysis of Vietnamese Patients with Mucopolysaccharidosis Type I
por: Ngoc Thi Bich Can, et al.
Publicado: (2021) -
Diagnostic imaging in patients with mucopolysaccharidosis: important imaging patterns
por: Igor I. Yarmola, et al.
Publicado: (2021) -
Activity of daily living in mucopolysaccharidosis IVA patients: Evaluation of therapeutic efficacy
por: Hui Chen, et al.
Publicado: (2021) -
Hyo-Mental Angle and Distance: An Important Adjunct in Airway Assessment of Adult Mucopolysaccharidosis
por: Chaitanya Gadepalli, et al.
Publicado: (2021)